Tetratherix Ltd (ASX: TTX) Share Price and News

Mr Gray is the Co-founder and Head of Strategic Growth, ANZ of Zip Co (ASX: ZIP). Drawing on more than 30 years of experience in the financial services industry, Mr Gray brings expertise in building and scaling innovative businesses within regulated environments. His career includes seven years as an ASX director.

Mr Kelly is an executive and company director with experience in the medical device industry, from ideation to advanced manufacturing and regulatory approval. He also spent five years at ResMed managing the New Product Implementation Group and helping develop the breakthrough Activa and Swift mask systems.

Mr Knox has over 20 years of leadership experience in the commercial development of medical technologies and healthcare innovations. His previous role was Senior Business Manager for Device Technologies following their acquisition of uHealth in 2017 - a regenerative biological company he established in 2013. Prior to founding uHealth, Will held commercial leadership roles at Medtronic (NYSE:MDT) and LifeHealthcare. Will currently holds the role of non-executive director of CathRx Limited and is a General Partner of Bioshore Ventures Pty Ltd. - an investor and operator of early-stage medical and biotech companies.

Ms Shea has over 25 years of audit and financial reporting experience and was a Registered Company Auditor. She was an audit partner at BDO where she had numerous ASX listed clients. Prior to BDO, Gillian was Director of EY in their Assurance practice. She is currently a Nonexecutive director of the Macular Disease Foundation of Australia, Non-executive director of Stone and Chalk Limited. She is the Chair of the Risk Committee.

Mr Fathi prior to founding the Company, Ali held several positions with the University of Sydney from 2011 to 2016 initially as Researcher, then Industrial Research Manager and Assistant Lecturer.

Ms Daniel is a General Partner and Managing Director at Radar Ventures, an investor in the Company through Preference Shares, SAFE Notes, and Convertible Notes. A commercially minded venture capital investor, Atlanta cofounded Radar Ventures with Xero founder Rod Drury. Radar backs early-stage deep tech businesses across medical, sustainability and defence sectors. With a career spanning venture investment, enterprise SaaS, consumer technology, and branding, Atlanta brings expertise in scaling innovative, IP-driven businesses. Previous advisory roles include engagements with AIM, a developer of advanced laser systems integrated with AI, and Airwallex, a global payments and financial platform.

Ms Cleary is currently a nonexecutive director of Device Technologies and has been with that company for nearly 20 years, previously holding the positions of executive director / Chief Operating Officer (2016 to 2020) and Chief Financial Officer (2005 to 2016). During this period Emma was also non-executive director and vice chair of the Medical Technology Association of Australia. She is a Member of the Risk Committee.

Mr Vecchione is the Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation and General Partner at AdAstral Funds. Mr Vecchione has spent the last 30 years at the forefront of biomedicine. His prior experience includes being Chief Executive Officer at Arrogene Nanotechnology, CompuMED, Trestle and multiple other science companies.

-

-

-

-